Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

NCT02824198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever
Dengue Hemorrhagic Fever

Interventions

BIOLOGICAL: CYD Dengue Vaccine (5 dose formulation)
BIOLOGICAL: Placebo, NaCl 0.9%

Sponsor

Sanofi Pasteur, a Sanofi Company